AbbVie’s proposed buyout of Ireland-based Shire still seems likely to go through, although new government rules concerning tax-inversion deals have made the deal less appealing to shareholders.
read more
AbbVie’s proposed buyout of Ireland-based Shire still seems likely to go through, although new government rules concerning tax-inversion deals have made the deal less appealing to shareholders.
read more